Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

natera inc - NTRA

NTRA

Close Chg Chg %
167.88 2.51 1.50%

Open Market

170.39

+2.51 (1.50%)

Volume: 604.47K

Last Updated:

Nov 21, 2024, 1:12 PM EDT

Trade Now

Company Overview: natera inc - NTRA

NTRA Key Data

Open

$170.00

 Day Range

164.40 - 171.95

52 Week Range

53.62 - 169.71

 Market Cap

$22.16B

Shares Outstanding

132.02M

 Public Float

123.98M

Beta

1.53

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.77

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.41M

  

NTRA Performance

1 Week
 
 14.94%
 
1 Month
 
 37.16%
 
3 Months
 
 36.81%
 
1 Year
 
 205.24%
 
5 Years
 
 329.58%
 

NTRA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 20
Full Ratings ➔

About natera inc - NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

NTRA At a Glance

Natera, Inc.
Building A, 13011 McCallen Pass
Austin, Texas 78753
Phone 1-650-980-9190 Revenue 1.08B
Industry Medical Specialties Net Income -434,801,000.00
Sector Health Technology 2023 Sales Growth 31.985%
Fiscal Year-end 12 / 2024 Employees 3,293
View SEC Filings

NTRA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 6.654
Price to Book Ratio 9.787
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -16.709
Enterprise Value to Sales 6.25
Total Debt to Enterprise Value 0.065

NTRA Efficiency

Revenue/Employee 328,749.165
Income Per Employee -132,037.959
Receivables Turnover 3.89
Total Asset Turnover 0.754

NTRA Liquidity

Current Ratio 4.096
Quick Ratio 3.963
Cash Ratio 2.861

NTRA Profitability

Gross Margin 45.516
Operating Margin -40.973
Pretax Margin -40.139
Net Margin -40.164
Return on Assets -30.282
Return on Equity -59.114
Return on Total Capital -36.014
Return on Invested Capital -39.903

NTRA Capital Structure

Total Debt to Total Equity 57.752
Total Debt to Total Capital 36.609
Total Debt to Total Assets 30.333
Long-Term Debt to Equity 45.728
Long-Term Debt to Total Capital 28.987
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Natera Inc - NTRA

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
391.00M 625.49M 820.22M 1.08B
Sales Growth
+29.33% +59.97% +31.13% +31.99%
Cost of Goods Sold (COGS) incl D&A
203.62M 318.42M 456.26M 589.83M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
8.61M 11.25M 30.47M 38.62M
Depreciation
8.61M 11.25M 30.47M 38.62M
Amortization of Intangibles
- - - -
-
COGS Growth
+16.04% +56.38% +43.29% +29.28%
Gross Income
187.38M 307.07M 363.97M 492.74M
Gross Income Growth
+47.71% +63.87% +18.53% +35.38%
Gross Profit Margin
+47.92% +49.09% +44.37% +45.52%
2020 2021 2022 2023 5-year trend
SG&A Expense
403.66M 739.64M 895.72M 936.31M
Research & Development
100.03M 228.60M 307.13M 318.00M
Other SG&A
303.63M 511.03M 588.59M 618.31M
SGA Growth
+57.70% +83.23% +21.10% +4.53%
Other Operating Expense
- - - -
-
Unusual Expense
5.85M 35.60M 9.29M 2.68M
EBIT after Unusual Expense
(222.13M) (468.17M) (541.04M) (446.24M)
Non Operating Income/Expense
7.56M 5.38M 3.54M 24.35M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
15.08M 8.30M 9.32M 12.64M
Interest Expense Growth
+41.05% -44.93% +12.21% +35.62%
Gross Interest Expense
15.08M 8.30M 9.32M 12.64M
Interest Capitalized
- - - -
-
Pretax Income
(229.65M) (471.10M) (546.82M) (434.53M)
Pretax Income Growth
-86.96% -105.14% -16.07% +20.54%
Pretax Margin
-58.73% -75.32% -66.67% -40.14%
Income Tax
98.00K 618.00K 978.00K 271.00K
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - 98.00K
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(229.74M) (471.72M) (547.80M) (434.80M)
Minority Interest Expense
- - - -
-
Net Income
(229.74M) (471.72M) (547.80M) (434.80M)
Net Income Growth
-84.05% -105.32% -16.13% +20.63%
Net Margin Growth
-58.76% -75.42% -66.79% -40.16%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(229.74M) (471.72M) (547.80M) (434.80M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(229.74M) (471.72M) (547.80M) (434.80M)
EPS (Basic)
-2.836 -5.209 -5.5666 -3.781
EPS (Basic) Growth
-58.03% -83.67% -6.87% +32.08%
Basic Shares Outstanding
81.01M 90.56M 98.41M 115.00M
EPS (Diluted)
-2.836 -5.209 -5.5666 -3.781
EPS (Diluted) Growth
-58.03% -83.67% -6.87% +32.08%
Diluted Shares Outstanding
81.01M 90.56M 98.41M 115.00M
EBITDA
(207.66M) (421.32M) (501.28M) (404.95M)
EBITDA Growth
-71.09% -102.88% -18.98% +19.22%
EBITDA Margin
-53.11% -67.36% -61.11% -37.41%

Snapshot

Average Recommendation BUY Average Target Price 169.176
Number of Ratings 20 Current Quarters Estimate -0.493
FY Report Date 12 / 2024 Current Year's Estimate -1.634
Last Quarter’s Earnings -0.26 Median PE on CY Estimate N/A
Year Ago Earnings -3.78 Next Fiscal Year Estimate -1.225
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 18 16 18 18
Mean Estimate -0.49 -0.41 -1.63 -1.22
High Estimates -0.31 -0.25 -1.42 -0.33
Low Estimate -0.67 -0.63 -2.02 -2.16
Coefficient of Variance -18.08 -28.62 -8.11 -43.68

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 15 15 15
OVERWEIGHT 4 4 3
HOLD 0 0 1
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Buy Buy Buy

Insider Actions for Natera Inc - NTRA

Date Name Shares Transaction Value
Oct 4, 2024 Jonathan Sheena Director 58,457 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $124.89 per share 7,300,694.73
Oct 4, 2024 Jonathan Sheena Director 58,161 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $125.23 per share 7,283,502.03
Oct 4, 2024 Jonathan Sheena Director 283,865 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $124.82 per share 35,432,029.30
Oct 4, 2024 Jonathan Sheena Director 282,041 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $126.42 per share 35,655,623.22
Oct 4, 2024 Jonathan Sheena Director 57,432 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $125.95 per share 7,233,560.40
Oct 4, 2024 Jonathan Sheena Director 57,432 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $126.27 per share 7,251,938.64
Oct 4, 2024 Jonathan Sheena Director 282,468 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $125.83 per share 35,542,948.44
Jul 18, 2024 Stephen Chapman CEO AND PRESIDENT; Director 207,855 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $112.2 per share 23,321,331.00
Jul 18, 2024 Stephen Chapman CEO AND PRESIDENT; Director 208,081 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $111.63 per share 23,228,082.03
Jul 3, 2024 Gail B. Marcus Director 21,598 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 James Irvin Healy Director 45,674 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Herman Rosenman Director 65,381 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Rowan E. Chapman Director 7,969 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Matthew Rabinowitz SEC. AND CHIEF LEGAL OFFICER 209,495 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 3, 2024 Matthew Rabinowitz SEC. AND CHIEF LEGAL OFFICER 206,772 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $108.37 per share 22,407,881.64
Jul 3, 2024 Ruth Williams-Brinkley Director 2,964 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Matthew Rabinowitz SEC. AND CHIEF LEGAL OFFICER 5,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 3, 2024 Roy D. Baynes Director 15,540 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Stephen Chapman CEO AND PRESIDENT; Director 215,782 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $108.61 per share 23,436,083.02
Jul 3, 2024 Roelof Frederik Botha Director 3,330 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Natera Inc in the News